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In a comparison of policy issues related to genomics and 
stem cells, initially, the differences seem to occupy the 
foreground. After all, no one is seeking to criminalize the 
conduct of genomic research, whereas researchers work­
ing with human embryonic stem cells face the prospect 
of criminal penalties in certain jurisdictions. And, in the 
USA, a polarized political climate, and twists and turns in 
litigation centering on a statutory provision that prohibits 
federal funding of ‘research in which a human embryo or 
embryos are destroyed’ [1], have heightened a sense of 
insecurity in the stem cell field [2]. However, stem cell 
policy  concerns  have  always  extended  beyond  the 
embryo. Furthermore, with the expansion of work using 
human induced pluripotent stem cells, created without 
embryo  destruction,  it  is  becoming  increasingly  likely 
that policy discussion around stem cells and genomics 
will converge in significant respects. I would suggest that 
five areas of concern are salient to both fields: (1) com­
mu  ni  cation,  (2)  consent,  (3)  consultation,  (4)  commer­
ciali  zation, and (5) clinical integration.
Communication
Significant  sums  of  public  money  have  been  and  are 
being  invested  in  genomic  and  stem  cell  research. 
Perhaps most attention­grabbing in the USA have been 
the Human Genome Project and the California Stem Cell 
Research  and  Cures  Initiative  (10  years  of  funding, 
approved  by  ballot  in  2004),  each  with  a  price  tag  of 
approximately  $3  billion.  Given  a  perception  that 
members of the public are motivated less by a thirst for 
fundamental  knowledge  than  a  desire  for  cures  for 
diseases,  enthusiasts  have  not  always  been  modest  in 
their assessments of the scope or speed of progress to be 
expected on the clinical front [3]. Yet this communication 
strategy,  successful  in  building  public  support  in  the 
short term, has the potential to backfire down the road. 
For example, in California, what will happen in 2014, or 
2017 (granting an additional 3 years for time lost to legal 
battles), if patients with paralysis have yet to walk and 
patients with diabetes are still going blind? Tempering 
enthusiasm with caution could help to avoid boom­and­
bust  cycles  in  which  public  generosity  gives  way  to 
disappointment  and  loss  of  funding.  Still,  there  is  a 
difference between resisting pressure to exaggerate the 
ease of finding cures and dampening down all excitement 
about the clinical potential of dramatic advances in basic 
science. The task is to find a way of harnessing public 
hopes and support for investment in scientific research to 
achieve  realistic  longer­term  goals  for  improvement  in 
clinical care and outcomes.
Consent
How much time and effort have policy bodies and insti­
tutional review boards invested in specifying conditions 
for  informed  consent  for  research  uses  of  human 
biological material and personal information? I have not 
seen a calculation, but it seems likely that the investment 
has been substantial. So it is interesting and perhaps also 
disheartening  that  consensus  on  consent  has  proven 
elusive. A recent review article focusing on genetics and 
genomics presents five competing options for informed 
consent for research uses of biological material and infor­
mation: deference to local review board determinations; 
categorical consent (that is, permitting donors to impose 
restrictions);  blanket  consent;  opt­out;  and  no  consent 
beyond any authorization related to initial collection [4]. 
Consensus has been difficult to achieve, in part because 
the risks of participation are somewhat intangible. The 
chance  that  even  ‘de­identified’  information  might  be 
linked to an individual by third parties, and this could 
lead to discrimination or other harm, or the possibility 
that a person’s DNA or data could end up contributing to 
research to which he or she objects, may seem insigni­
ficant to some. Yet such matters matter ­ scandals have 
arisen and biorepositories have been destroyed due to the 
efforts of individuals surprised to learn that they or their 
loved ones have been unwitting subjects of research. A 
literature is now developing around consent for stem cell 
research  that  cites  concerns  about  respect  for  persons 
and  privacy  that  are  similar  to  concerns  related  to  © 2010 BioMed Central Ltd
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and  embryo  donation  (for  example,  treatment  of  third 
party gamete donors) [7].
Consultation
There is a growing emphasis internationally on consul­
tation with those most affected and the public at large 
across many areas of science. The sorts of activities used 
for  consultation  are  diverse,  ranging  from  traditional 
surveys,  opinion  polling  and  focus  groups  to  citizen 
consensus conferences, ‘deliberative polling’ and other 
forms  of  dialogical,  substantive  public  engagement. 
Furthermore,  the  purposes  of  such  consultation  fall 
within  a  spectrum  from  placating  interest  groups  or 
craft  ing more effective means of marketing science to 
giving  citizens  a  more  direct  role  in  guiding  public 
investment in science or enlisting them in the ‘upstream’ 
planning  and  policy  setting  for  major  research 
initiatives.  In  human  genomics,  consultation  efforts 
have  been  linked  to  the  creation  of  population­based 
biobanks or databases, while in the stem cell field, topics 
for dialogue have included oocyte and embryo donation 
and  the  creation  of  human­non­human  animal 
chimeras. Stem­cell derived gametes may soon be added 
to the agendas of such consultations, especially given 
the  potential  for  combination  with  techniques  for 
genetic modification [8].
Commercialization
In a recent statement on data and materials sharing and 
intellectual  property  in  stem  cell  science,  the  Hinxton 
Group  provides  a  useful  summary  of  concerns  at  the 
intersection  of  science  and  commerce  [9].  Consider 
patents. Restrictions on liberty via policies that allow for 
patenting inventions are often justified with reference to 
the  incentives  that  patents  create  for  innovation.  In 
recent years some have argued that patents and propri  e­
tary tendencies may actually be hampering innovation, as 
well  as  creating  financial  barriers  to  access  when 
inventions finally make it to market (whether high prices 
reflect  the  producer’s  exploitation  of  its  own  patents 
through monopoly pricing or the producer’s need to pay 
significant royalties to other patent holders). To address 
these concerns, the Hinxton Group proposes a number 
of remedial steps, including: a global resource to facilitate 
access to registry information; a central hub for patent 
information;  exploration  of  options  for  collective 
management  of  intellectual  property,  including  patent 
pools  and  a  norm  of  non­exclusive  licensing;  and  re­
assess  ment  of  current  standards  for  granting  patents. 
Similar issues have arisen in the context of genomics [10], 
and the Hinxton Group urges emulation of models that 
have emerged there, for example, resources for sharing of 
DNA sequence information.
Clinical integration
One of the next policy frontiers is surely clinical integra­
tion of the results of basic and translational research in 
the two fields. Given the current fiscal crises at all levels 
of  government,  and  the  potential  for  steep  pricing,  it 
seems likely that considerable energy in the future will 
be directed to determining whether better diagnostics 
or cures can be achieved within a sustainable system of 
health care. Ideally, the discussion will center on cost­
effectiveness (which interventions deliver good value for 
money) and equity (can we assure that benefits reach 
those with the greatest need). It is entirely possible that 
policy  will  instead  be  driven  by  cost  alone  and  that 
bene  fits  will  be  concentrated  among  those  already 
advantaged  ­  unless  consultation  moves  policy  in  the 
direction of fairness.
If these areas of concern are indeed common, there is 
the  potential  for  mutual  learning,  and  to  the  extent 
sensible and feasible, harmonization of the policies that 
shape both fields.
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